28 Jun 2024 — The second clinical trial on Gencor’s highly bioavailable form of palmitoylethanolamide (PEA) ingredient, Levagen+, for the active nutrition category, observed that it significantly improves lower body power and does not interfere with skeletal muscle hypertrophy gains.